Anti-arrhythmic peptide N-3-(4-hydroxyphenyl)propionyl Pro-Hyp-Gly-Ala-Gly-OH reduces dispersion of action potential duration during ischemia/reperfusion in rabbit hearts

Journal of Cardiovascular Pharmacology

Volumn 40, Issue 5, 2002, Pages 770-779

  Kjølbye, Anne Louise ^a   Holstein Rathlou, Niels Henrik ^b   Petersen, Jørgen Søberg ^a  

^a Zealand Pharma AS   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Anti arrhythmic therapy; Gap junctions; Ventricular fibrillation

Indexed keywords

ANTIARRHYTHMIC AGENT; N 3 (4 HYDROXYPHENYL)PROPIONYLPROLYLHYDROXYPROLYLGLYCYLALANYLGLYCINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; HEART LEFT VENTRICLE MASS; HEART MUSCLE CONTRACTILITY; HEART MUSCLE PERFUSION; HEART MUSCLE POTENTIAL; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HYPOKALEMIA; ISCHEMIC HEART DISEASE; MALE; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; RABBIT;

ACTION POTENTIALS; ALPHA-DEFENSINS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; HEART; HEMODYNAMIC PROCESSES; ISCHEMIA; MALE; MYOCARDIAL CONTRACTION; RABBITS;

EID: 0036872337     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200211000-00015     Document Type: Article

References (25)

1. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL: Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
2. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction: The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996;348:7-12.
3. Guerrero PA, Schuessler RB, Davis LM, Beyer EC, Johnson CM, Yamada KA, Saffitz JE: Slow ventricular conduction in mice heterozygous for a connexin43 null mutation. J Clin Invest 1997;99:1991-8.
4. Lerner DL, Yamada KA, Schuessler RB, Saffitz JE: Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circulation 2000;101:547-52.
5. Beardslee MA, Lerner DL, Tadros PN, Laing JG, Beyer EC, Yamada KA, Kleber AG, Schuessler RB, Saffitz JE: Dephsphorylation and intracellular redistribution of ventricular connexin43 during electrical uncouphng induced by ischemia. Circ Res 2000 Oct 13;87:656-62.
6. Huang XD, Sandusky GE, Zipes DP: Heterogeneous loss of connexin43 protein in ischemic dog hearts. J Cardiovasc Electrophysiol 1999;10:79-91.
7. Kaprielian RR, Gunning M, Dupont E, Sheppard MN, Rothery SM, Underwood R, Pennell DJ, Fox K, Pepper J, Poole-Wilson PA, Severs, NJ: Downregulation of immunodetectable connexin43 and decreased gap junction size in the pathogenesis of chronic hibernation in the human left ventricle. Circulation 1998;97:651-60.
8. Peters NS, Green CR, Poole-Wilson PA, Severs NJ: Reduced content of connexin43 gap junctions in ventricular myocardium from hypertrophied and ischemic human hearts. Circulation 1993;88:864-75.
9. Peters NS, Coromilas J, Severs NJ, Wit AL: Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation 1997;95:988-96.
10. Gottwald E, Gottwald M, Dhein S: Enhanced dispersion of epicardial activation-recovery intervals at sites of histological inhomogeneity during regional cardiac ischaemia and reperfusion. Heart 1998;79:474-80.
11. Kuo CS, Munakata K, Reddy CP, Surawicz B: Characteristics and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential durations. Circulation 1983;67:1356-67.
12. Merx W, Yoon MS, Han J: The role of local disparity in conduction and recovery time on ventricular vulnerability to fibrillation. Am Heart J 1977;94:603-10.
13. Lesh MD, Pring M, Spear JF: Cellular uncoupling can unmask dispersion of action potential duration in ventricular myocardium. A computer modeling study. Circ Res 1989;65:1426-40.
14. Dhein S, Krusemann K, Schaefer T: Effects of the gap junction uncoupler palmitoleic acid on the activation and repolarization wavefronts in isolated rabbit hearts. Br J Pharmacol 1999;128:1375-84.
15. Wolk R, Cobbe SM, Hicks MN, Kane KA: Functional, structural, and dynamic basis of electrical heterogeneity in healthy and diseased cardiac muscle: implications for arrhythmogenesis and anti-arrhythmic drug therapy. Pharmacol Ther 1999;84:207-31.
16. Dhein S, Tudyka T: Therapeutic potential of antiarrhythmic peptides. Cellular coupling as a new antiarrhythmic target. Drugs 1995;49:851-5.
17. Aonuma S, Kohama Y, Makino T, Fujisawa Y: Studies of heart. XXI. Amino acid sequence of antiarrhythmic peptide (AAP) isolated from atria. J Pharmacobiodyn 1982; 5:40-8.
18. Aonuma S, Kohama Y, Akai K, Komiyama Y, Nakajima S, Wakabayashi M, Makino T: Studies on heart. XIX. Isolation of an atrial peptide that improves the rhythmicity of cultured myocardial cell clusters. Chem Pharm Bull (Tokyo) 1980;28:3332-9.
19. Dhein S, Manicone N, Muller A, Gerwin R, Ziskoven U, Irankhahi A, Minke C, Klaus W: A new synthetic antiarrhythmic peptide reduces dispersion of epicardial activation recovery interval and diminishes alterations of epicardial activation patterns induced by regional ischemia. A mapping study. Naunyn Schmiedebergs Arch Pharmacol 1994;350:174-84.
20. Dikshit M, Srivastava R, Kundu B, Mathur KB, Kar K: Antiarrhythmic and antithrombotic effect of antiarrhythmic peptide and its synthetic analogues. Indian J Exp Biol 1988;26:874-6.
21. Kohama Y, Okimoto N, Mimura T, Fukaya C, Watanabe M, Yokoyama K: A new antiarrhythmic peptide, N-3-(4-hydroxyphenyl)propionyl Pro-Hyp-Gly-Ala-Gly. Chem Pharm Bull (Tokyo) 1987;35:3928-30.
22. Kohama Y, Kuwahara S, Yamamoto K, Okabe M, Mimura T, Fukaya C, Watanabe M, Yokoyama K: Effect of N-3-(4-hydroxyphenyl)propionyl Pro-Pro-Gly-Ala-Gly on calcium-induced arrhythmias. Chem Pharm Bull (Tokyo) 1988;36:4597-9.
23. Argentieri T, Cantor E, Wiggins JR: Antiarrhythmic peptide has no direct cardiac actions. Experientia 1989;45: 737-8.
24. Muller A, Schaefer T, Linke W, Tudyka T, Gottwald M, Klaus W, Dhein S: Actions of the antiarrhythmic peptide AAP10 on intercellular coupling. Naunyn Schmiedebergs Arch Pharmacol 1997;356:76-82.
25. Muller A, Gottwald M, Tudyka T, Linke W, Klaus W, Dhein S: Increase in gap junction conductance by an antiarrhythmic peptide. Eur J Pharmacol 1997;327:65-72.